Dasatinib may exert inhibitory effects on ARID1A‐deficient tumour cells by regulating the cell cycle regulatory network associated with cyclin—dependent kinase inhibitor 1A (CDKN1A) and RB1 [31]. Here, CDKN1A is linked to neoplasm.